Adaptive Technologies Corporation (NASDAQ: ADPT) presented data on T-cell receptor sequences related to Crohn’s disease (CD) during the 17th Congress of European Crohn’s and Colitis Organisation oral presentation between February 16 and 19, 2022.
ImmmunoSEQ tech used to identify and analyze CD-related TCR sequences
The company’s immunoSEQ tech was used to identify and analyze TCR sequences linked with CD, offering an essential understanding of the body’s reaction to CD at the molecular level.
The immunoSEQ test employs sequencing technologies to unravel the adaptive immune system’s complexity. ImmunoSEQ tech was used to assess TCRs from samples taken of 1,738 CD patients and 4,970 healthy volunteers in the multi-national study, published in The Journal of Crohn’s and Colitis. In addition, a selection of 380 cases had their intestinal tissue samples examined as well. Through research, 1,121 CD-related TCRs in patients’ blood were discovered and confirmed in tissue. The discovery of disease-specific TCRs is a critical initial step to identifying a signal and formulating an algorithm that will enable the development of a CD diagnostic test.
The researchers discovered Crohn’s-specific TCRs in the tissue and blood of Crohn’s disease patients, including a sizable portion that is ‘public,’ or shared by all patients. The results suggest that by identifying illness-specific T-cell receptors, blood-based diagnostics for this debilitating condition could be utilized to diagnose and better manage the disease.
T Cell play a role in CD inflammation
T cells can play a substantial role in CD irritation, but disease-related TCRs have been mostly unexplored and underutilized in CD diagnosis until now. 1 These results reveal that immunoSEQ can identify CD TCRs in a blood sample, which corresponds to TCRs in the intestinal mucosa.
Chief Scientific Officer of the company Harlan Robins said We’re excited to see these results and their potential to advance the scientific community’s understanding of the immune response to Crohn’s disease. In addition, the use of immunoSEQ and characterization of TCRs in the blood have the potential to uncover new knowledge on the development and progression of the disease, with the potential to eventually improve diagnostic options and disease management for people living with Crohn’s.”
